Latest: Watch here for details of new products and services.
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Phytohealth Corporation: PH3 (PHN031, PHN033) - For osteoporosis and diabetic vascular complications
Patented technology regarding new and safe mechanism with the active substance PH3 for the indications of osteoporosis and diabetic vascular complications. More
A non-invasive development of a test for the diagnosis and monitoring of endometriosis. More
A number of specific PPLs, a group of prenylflavanone compounds, some novel, were isolated, identified and tested at as low as 0.04 μg/mL to be able to increase survival of neural stem cells, to promote neuronal growth with lengthening of neurite More
Novel target and monoclonal antibody for early diagnosis and/or therapeutic intervention More
Western inventors have identified a group of 12 differentially expressed proteins in Preeclampsia (PE) patients using a state-of-art proteomics based approach. More
Blood genetic marker for predicting restenosis after the use of heart stents More
Diagnostic assay for early detection of nephropathy related to diabetes and other nephropathy-associated disorders. More
A neuron-specific tau kinase involved in tau hyperphosphorylation and aggregation. More
Neomics has found a very promising target, AIMP2/AIMP2-DX2 for siRNA therapy application to tumoric lung cancer cells and we intend to focus the remaining resources on developing through clinical trials, the siRNA therapy as a first priority More
This invention concerns identification of the first serum tumour marker for monitoring the initiation and progression of prostate cancer (CaP) in animal models. More
Your selection
Browse By
- Therapeutic target
- Accident and Trauma
- Allergy
- Blood and forming organs
- Cardiovascular
- Central Nervous System
- Dermatological
- Endocrinology
- Gastrointestinal
- Genetic disorders
- Genito-urinary
- Hospital and Surgery
- Immune related disorders
- Infectious diseases
- Metabolism
- Musculoskeletal
- Oncology
- Oral Health
- Other therapeutic
- Respiratory
- Sensory organ
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us